查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933846

内视镜减重市场依治疗类型、产品类型、手术环境和最终用户划分，全球预测（2026-2032）

Endoscopic Weight Loss Therapy Market by Therapy Type, Product Type, Procedure Setting, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年内视镜减重治疗市场价值为 3.1758 亿美元，预计到 2026 年将增长至 3.5803 亿美元，预计到 2032 年将达到 6.5074 亿美元，复合年增长率为 10.79%。

关键市场统计数据
基准年 2025 3.1758亿美元
预计年份：2026年 3.5803亿美元
预测年份 2032 6.5074亿美元
复合年增长率 (%) 10.79%

将当代内视镜减重治疗定位为一种微创选择，从而重塑临床路径和相关人员的优先事项。

内视镜减重方法已从实验性技术发展成为系统性的临床路径，融合了胃肠病学、减重手术和门诊手术等多个领域。新兴技术将肥胖视为一种可透过微创内视镜干预治疗的疾病，治疗方案也从纯粹的外科手术转向强调降低併发症风险、加快康復速度以及在临床适宜的情况下可重复治疗的内视镜手术。这一发展趋势正迫使包括医疗设备製造商、支付方和多学科医疗团队在内的众多相关人员重新评估临床诊疗流程和病患选择标准。

了解近年来在器械创新、治疗路径整合和实证医学证据生成方面发生的变革性变化，这些变化促成了内视镜肥胖治疗的广泛应用。

内视镜减重领域正经历着变革性的转变，这主要得益于设备平台的创新、临床实践模式的演变以及跨学科合作的加强。製造商不断改进缝合、钉合、吸引和胃内系统，以提高安全性，同时简化使用者介面，促进更广泛的应用。这使得学习曲线更短，门诊和日间手术中心的应用率更高，并支持了更多临床医生参与，而不仅限于专科三级医疗机构。

分析2025年美国关税调整将如何重塑内视镜供应链中的设备采购、定价动态与筹资策略。

美国在2025年前实施的关税措施和贸易政策调整，为依赖全球医疗设备供应链的供应商和医疗机构带来了新的营运挑战。某些进口零件关税的提高可能会影响内视镜系统的成本结构，尤其是在专用工具和精密耗材采购自国际製造地的情况下。这使得医疗机构和采购团队面临更大的压力，需要重新评估供应商合同，协商长期协议，并考虑除单位成本之外的总到岸成本的影响。

详细的細項分析揭示了治疗亚型、产品分类和临床环境如何共同影响临床应用和商业化策略。

按治疗方法类型分類的市场细分突显了真空辅助、内视镜袖状胃成形术和胃内球囊治疗各自不同的临床作用和技术要求。以AspireAssist平台等系统为代表的真空辅助手术强调持久的引流介面和病患自主管理通讯协定，其所需的训练和追踪与医师操作的手术有所不同。内视镜袖状胃成形术分为缝合系统和吻合器系统，每种系统在器械易用性、资金投入需求和临床学习曲线方面均有所不同，这会影响胃肠病学家和减肥手术团队的采纳决策。胃内球囊进一步分为长期使用和短期使用，长期使用的器械强调持续放置和可回收设计，而短期球囊治疗则侧重于暂时性容量替代，手术复杂度较低。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势和应用驱动因素将影响部署、报销和扩大策略。

区域趋势显着影响内视镜减重疗法在医疗保健系统中的推广、报销和普及。在美洲，成熟的临床网络和相对较高的肥胖盛行率为早期应用奠定了基础，加之支付方对经济高效、微创治疗方法的日益关注，使得该疗法得以迅速普及。该地区的医疗机构正在门诊项目中增加试点项目，并将相关设备整合到多学科体重管理流程中，从而加快临床医生技能的提升和患者的转诊。

竞争动态、伙伴关係以及以证据为导向的商业策略将决定哪些公司主导市场采用并维持长期的市场地位。

内视镜减重治疗产业的格局是由竞争与合作并存的动态所塑造。领先的设备开发人员致力于提升手术安全性、简化使用者介面，并透过研究者主导的临床试验和註册研究来拓展实证医学证据基础。同时，设备供应商与临床网路之间的策略联盟加速了培训计画的发展，扩大了早期采用者试点机构的覆盖范围，并促成了可操作数据的收集，从而为与支付方的沟通提供依据。併购仍是领先企业获取差异化技术、建构涵盖耗材、资本设备和数位化病人参与工具等全面产品组合的有效途径。

整合临床证据、训练、供应链韧性和支付方参与，以促进内视镜减重手术广泛应用的实用策略建议

产业领导者应采取协作策略，整合临床证据产生、支付方参与和营运部署，以加速内视镜减重疗法的合理推广。首先，应优先进行前瞻性、真实世界研究和多中心註册研究，以收集持续的患者疗效和医疗成本指标。可靠的疗效数据将显着增强医保报销谈判的力度，并提升临床医师的信心。其次，应投资于可扩展的临床医生培训项目，结合实践模拟、指导和数位化技能开发，以减少操作差异，并缩短不同医疗机构的推广应用曲线。

严谨的混合方法整合了临床医生访谈、监管审查和三角验证的证据，以得出检验的研究结果和局限性。

本调查方法结合了质性研究和系统性的二手研究，以确保结论的全面性和检验。质性研究包括对临床医生、医院采购人员、门诊手术经理和医疗设备製造商高阶主管进行结构化访谈，并辅以与多学科咨询委员会的讨论。这些工作为了解手术流程、培训需求、报销谈判和采购决策标准提供了背景资讯。访谈涵盖了不同的地理和医疗机构类型，以收集多元化的营运观点。

摘要强调，协调的证据、报销的协调以及运作准备是内视镜治疗可持续推广的先决条件。

总之，内视镜减重疗法正处于一个关键的转折点，其发展受到技术改进、实证医学证据日趋成熟以及医疗服务经济模式变化的影响。设备人体工学的改进、可操作性结果研究的开展以及培训基础设施的完善，共同提高了该疗法在专科三级医疗中心之外推广应用的可能性。然而，要实现常规临床应用，则取决于实证医学证据的产生、支付方的合作以及供应链的韧性等方面的协调行动。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 内视镜减重减重市场（依治疗方法）

  • 吸痰疗法
  • 内视镜袖状胃成形术
    • 装订系统
    • 缝合系统
  • 胃内球囊
    • 长期气球
    • 短期气球

9. 依产品类型分類的内视镜减重减重市场

  • 可重复使用的气球
  • 免洗气球

第十章 依治疗环境分類的内视镜减重减重市场

  • 住院治疗
  • 门诊

第十一章 按最终用户分類的内视镜减重治疗市场

  • 门诊手术中心
    • 独立中心
    • 医院附设中心
  • 诊所
    • 肥胖治疗诊所
    • 胃肠病诊所
  • 医院
    • 大学医院
    • 社区医院
  • 减重中心
    • 多学科合作中心
    • 单一治疗中心

第十二章 各地区内视镜减重减重市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 内视镜减重市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国内镜减重治疗市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国内视镜减重治疗市场

第十六章 中国内窥镜减重治疗市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Allurion Technologies, Inc.
  • Apollo Endosurgery, Inc.
  • Aspire Bariatrics, Inc.
  • Bariatric Solutions GmbH
  • Bariatric Solutions International
  • BDB Limited
  • Boston Scientific Corporation
  • ConMed Corporation
  • Cousin Biotech
  • Districlass Medical
  • Endalis
  • Fractyl Health
  • GI Dynamics, Inc.
  • Helioscopie Medical Implants
  • Intuitive Surgical
  • Johnson & Johnson
  • Lexel Medical
  • MEDSIL
  • Medtronic plc
  • Obalon Therapeutics, Inc.
  • Olympus Corporation
  • ReShape Lifesciences, LLC
  • Silimed
  • Spatz FGIA
  • Spatz Medical Ltd.
  • USGI Medical, Inc.
  • WL Gore & Associates
Product Code: MRR-C36616F6997C

The Endoscopic Weight Loss Therapy Market was valued at USD 317.58 million in 2025 and is projected to grow to USD 358.03 million in 2026, with a CAGR of 10.79%, reaching USD 650.74 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 317.58 million
Estimated Year [2026] USD 358.03 million
Forecast Year [2032] USD 650.74 million
CAGR (%) 10.79%

Framing the modern trajectory of endoscopic weight loss interventions as minimally invasive options that reshape clinical pathways and stakeholder priorities

Endoscopic approaches to weight loss have matured from experimental techniques into structured clinical pathways that intersect gastroenterology, bariatrics, and ambulatory surgery. Emerging technologies now treat obesity as a condition amenable to minimally invasive endoluminal interventions, shifting care away from purely surgical solutions toward procedures that emphasize lower morbidity, quicker recovery, and repeatability when clinically appropriate. This evolution has invited a broader set of stakeholders-including device manufacturers, payers, and multidisciplinary care teams-to reassess clinical algorithms and patient selection criteria.

Clinicians increasingly view endoscopic therapies as complementary to lifestyle and pharmacologic interventions rather than as standalone endpoints. Consequently, iterative improvements in device design, procedural workflows, and post-procedure support models have focused attention on long-term patient engagement and outcome tracking. At the same time, regulatory pathways and reimbursement conversations have adapted to accommodate the growing evidence base, which in turn influences capital allocation and adoption pacing across care settings.

As we examine the landscape further, it becomes clear that the convergence of clinical need, technological refinement, and shifting provider economics has created an inflection point. Strategic stakeholders must therefore align clinical evidence generation, payer engagement, and commercialization strategies to realize the full potential of endoscopic weight loss therapies within contemporary care delivery models.

Understanding the recent transformative shifts in device innovation, care pathway integration, and evidence generation that enable broader adoption of endoscopic obesity interventions

The landscape of endoscopic weight loss therapy has experienced transformative shifts driven by innovation in device platforms, evolving clinical practice patterns, and strengthened interdisciplinary collaboration. Manufacturers have invested in iterative improvements across suturing, stapling, aspiration, and intragastric systems to enhance safety profiles while simplifying user interfaces for wider adoption. As a result, procedural learning curves have shortened, which facilitates diffusion into outpatient and ambulatory surgical settings and supports broader clinician participation beyond specialized tertiary centers.

Meanwhile, the integration of endoscopic therapies with structured weight management programs has shifted emphasis toward longitudinal care models. This movement encourages the deployment of digital health tools for patient engagement, remote monitoring, and outcomes assessment, thereby reinforcing the role of endoscopic therapies within comprehensive obesity management pathways. Additionally, regulatory clarity in several jurisdictions has allowed manufacturers and providers to pursue robust post-market evidence generation and pragmatic clinical studies that better reflect real-world practice.

Taken together, these shifts reduce barriers to clinical adoption and create new commercial pathways. Forward-looking stakeholders will therefore prioritize interoperability with care pathways, evidence-based reimbursement strategies, and partnerships that expand procedure accessibility across diverse clinical settings.

Analyzing how 2025 United States tariff adjustments reshape device sourcing, pricing dynamics, and procurement strategies across the endoscopic therapy supply chain

Recent tariff actions and trade policy adjustments within the United States for 2025 have introduced a new layer of operational complexity for suppliers and providers who rely on global medical device supply chains. Increased duties on select imported components can affect cost structures for endoscopic systems, particularly where specialized tooling and precision consumables are sourced from international manufacturing hubs. Accordingly, providers and procurement teams face heightened pressure to reassess supplier agreements, negotiate longer-term contracts, and examine total landed cost implications beyond unit price.

In response, manufacturers are exploring mitigation strategies that include supplier diversification, qualification of alternate component sources, and selective relocation of discrete manufacturing steps closer to major demand markets. These actions aim to insulate product availability and reduce exposure to tariff volatility. At the same time, some organizations will likely absorb incremental costs temporarily to maintain competitive pricing and market access, while others may implement measured price adjustments or revise service and consumable pricing models.

Importantly, increased tariffs intersect with reimbursement negotiations and capital purchasing cycles; providers must therefore anticipate procurement timing and evaluate the fiscal impact on capital acquisition decisions for new endoscopic platforms. In sum, trade policy changes in 2025 compel both vendors and healthcare purchasers to adopt more resilient sourcing strategies and proactive commercial planning to sustain supply continuity and predictable cost dynamics.

Detailed segmentation insights revealing how therapy subtypes, product classifications, and care settings collectively influence clinical adoption and commercialization strategies

Segmentation of the market by therapy type highlights distinct clinical roles and technological demands across aspiration therapy, endoscopic sleeve gastroplasty, and intragastric balloon solutions. Aspiration therapy, exemplified by systems like the AspireAssist platform, prioritizes durable drainage interfaces and patient-managed protocols that require different training and follow-up compared with operator-delivered procedures. Endoscopic sleeve gastroplasty divides into stapling systems and suturing systems, each introducing divergent device ergonomics, capital requirements, and clinical learning curves that influence adoption by gastroenterologists and bariatric teams. Intragastric balloons further bifurcate into long-term and short-term balloons; long-term devices emphasize sustained occupancy and retrievable designs while short-term balloons focus on temporary volume displacement with lower procedural complexity.

When viewed through the product-type lens, the market differentiates between reusable balloons and single-use balloons, a distinction that drives procurement preferences, sterilization workflows, and per-procedure cost calculus for facilities. Reusable platforms necessitate validated reprocessing capabilities and capital amortization, whereas single-use options sidestep reprocessing but require consistent supply reliability. From the end-user perspective, the procedure landscape spans ambulatory surgical centers, clinics, hospitals, and dedicated weight loss centers. Ambulatory surgical centers comprise freestanding sites and hospital-affiliated centers, clinics include bariatric and gastroenterology clinics, hospitals range from academic medical centers to community hospitals, and weight loss centers encompass multidisciplinary hubs and single-practice facilities. Finally, procedure setting segmentation into inpatient and outpatient care pathways shapes resource allocation, perioperative protocols, and patient throughput models.

Taken together, these segmentation dimensions inform product development priorities, clinical training programs, and commercialization strategies tailored to the operational realities of different provider types and procedure environments.

Regional dynamics and adoption drivers across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape deployment, reimbursement, and scaling strategies

Regional dynamics substantially influence how endoscopic weight loss therapies are introduced, reimbursed, and scaled across healthcare systems. In the Americas, established clinical networks and a relatively high prevalence of obesity have created fertile ground for early adoption, accompanied by growing payer interest in cost-effective, minimally invasive options. Providers in this region increasingly pilot outpatient programs and integrate devices into multidisciplinary weight management pathways, thereby accelerating clinician familiarity and patient referral flows.

Europe, Middle East & Africa display heterogeneous adoption patterns rooted in national reimbursement frameworks, variable procedural capacity, and differing regulatory timelines. Western European countries with clear reimbursement pathways tend to lead in technology uptake, while emerging markets within the region explore targeted deployment that aligns with local infrastructural capacities and specialist availability. The Middle East has shown interest in concentrated center-based programs, and parts of Africa focus on pilot initiatives tied to specialized centers.

In Asia-Pacific, rapid urbanization, expanding private healthcare sectors, and high unmet clinical need are driving interest in scalable endoscopic interventions. However, adoption varies with regulatory maturity and the availability of trained endoscopists. Cross-regionally, manufacturers must adapt market entry strategies to local payer structures and procedural workflows, and they must invest in clinician training and post-market evidence generation appropriate for each regulatory and reimbursement environment.

How competitive dynamics, partnerships, and evidence-focused commercial strategies determine which companies lead adoption and sustain long-term market presence

Competitive and collaborative forces define the company landscape supporting endoscopic weight loss therapy. Leading device developers concentrate on enhancing procedural safety, simplifying user interfaces, and broadening the evidence base through investigator-initiated studies and registries. At the same time, strategic partnerships between device suppliers and clinical networks have accelerated training programs, expanded access to early adopter sites, and enabled pragmatic data collection to inform payer conversations. Mergers and acquisitions remain a viable pathway for larger firms to acquire differentiated technologies and to build comprehensive portfolios that span consumables, capital equipment, and digital patient engagement tools.

Investors and corporate development teams evaluate companies based on technological differentiation, intellectual property protection, and the ability to execute robust post-market clinical programs. Meanwhile, smaller innovators often pursue niche strategies that target specific clinical indications or ergonomic improvements to win share within specialist practices. Importantly, supply chain reliability and regulatory compliance have become core competitive factors as providers demand predictable consumable availability and clear evidence of device lifecycle management. Overall, market participants that align clinical evidence generation with pragmatic commercialization and supply strategies position themselves favorably for sustained penetration across multiple care settings.

Actionable strategic recommendations for aligning clinical evidence, training, supply resilience, and payer engagement to drive scalable adoption of endoscopic obesity therapies

Industry leaders should adopt a coordinated strategy that aligns clinical evidence generation, payer engagement, and operational deployment to accelerate responsible adoption of endoscopic weight loss therapies. First, prioritize prospective real-world studies and multicenter registries that capture durable patient outcomes and cost-of-care metrics, because robust outcome data materially strengthen reimbursement discussions and clinician confidence. Second, invest in scalable clinician training programs that combine hands-on simulation, proctoring, and digital upskilling to reduce variability in procedural performance and to shorten adoption curves across diverse practice settings.

Concurrently, optimize supply chain resilience by qualifying multiple component sources, exploring regional manufacturing partnerships, and planning inventory buffers that reduce exposure to trade-related disruptions. Firms should also design flexible pricing and service models that consider differences between reusable and single-use products, as well as the distinct procurement priorities of ambulatory surgical centers versus hospitals. Finally, engage payers early with value dossiers that clearly articulate patient selection criteria, downstream cost implications, and real-world outcomes. By synchronizing evidence, training, supply operations, and payer narratives, organizations can create sustainable pathways to scale while maintaining high standards of patient safety and clinical effectiveness.

Rigorous mixed-method research approach integrating clinician interviews, regulatory review, and triangulated evidence to produce validated insights and limitations

The research methodology combines primary qualitative insight with systematic secondary analysis to ensure comprehensive, validated conclusions. Primary research involved structured interviews with clinicians, hospital procurement leaders, ambulatory surgery administrators, and device executives, supplemented by advisory board discussions with multidisciplinary specialists. These engagements provided context on procedure workflows, training needs, reimbursement conversations, and procurement decision criteria. Interviews were conducted across varied geographies and provider types to capture diverse operational perspectives.

Secondary research encompassed regulatory documents, peer-reviewed clinical literature, device instructions for use, and policy publications. Data triangulation occurred by cross-referencing interview inputs with published evidence and regulatory guidance to reduce bias and to validate emerging themes. Analytical techniques included thematic coding of qualitative inputs, comparative assessment of device features and procedural workflows, and scenario analysis for supply chain and policy impacts. The methodology also accounted for limitations, including variability in regional reimbursement landscapes and the evolving nature of long-term clinical outcome data. Ethical considerations and confidentiality agreements governed all primary interviews and data handling to protect participant anonymity and proprietary information.

Concluding synthesis that emphasizes coordinated evidence, reimbursement alignment, and operational readiness as prerequisites for sustainable adoption of endoscopic therapies

In conclusion, endoscopic weight loss therapy stands at a pivotal juncture shaped by technological refinement, evidence maturation, and changing care delivery economics. The cumulative effect of improved device ergonomics, pragmatic outcome studies, and expanded training infrastructures has increased the feasibility of broadening procedural access beyond specialized tertiary centers. Yet, the pathway to routine clinical integration hinges on coordinated action across evidence generation, payer engagement, and supply chain resilience.

Looking ahead, stakeholders who proactively align clinical development with reimbursement strategies and who invest in scalable training and post-procedure care models will most effectively translate innovation into routine practice. Trade policy shifts and regional heterogeneity in reimbursement require adaptive commercialization plans and localized value propositions. Ultimately, the successful diffusion of endoscopic obesity interventions will depend on demonstrable patient benefit, clear economic rationale for payers, and operational models that deliver reliable, high-quality care across diverse clinical settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Endoscopic Weight Loss Therapy Market, by Therapy Type

  • 8.1. Aspiration Therapy
  • 8.2. Endoscopic Sleeve Gastroplasty
    • 8.2.1. Stapling Systems
    • 8.2.2. Suturing Systems
  • 8.3. Intragastric Balloon
    • 8.3.1. Long-Term Balloons
    • 8.3.2. Short-Term Balloons

9. Endoscopic Weight Loss Therapy Market, by Product Type

  • 9.1. Reusable Balloons
  • 9.2. Single-Use Balloons

10. Endoscopic Weight Loss Therapy Market, by Procedure Setting

  • 10.1. Inpatient
  • 10.2. Outpatient

11. Endoscopic Weight Loss Therapy Market, by End User

  • 11.1. Ambulatory Surgical Centers
    • 11.1.1. Freestanding Centers
    • 11.1.2. Hospital Affiliated Centers
  • 11.2. Clinics
    • 11.2.1. Bariatric Clinics
    • 11.2.2. Gastroenterology Clinics
  • 11.3. Hospitals
    • 11.3.1. Academic Hospitals
    • 11.3.2. Community Hospitals
  • 11.4. Weight Loss Centers
    • 11.4.1. Multidisciplinary Centers
    • 11.4.2. Single Practice Centers

12. Endoscopic Weight Loss Therapy Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Endoscopic Weight Loss Therapy Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Endoscopic Weight Loss Therapy Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Endoscopic Weight Loss Therapy Market

16. China Endoscopic Weight Loss Therapy Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Allurion Technologies, Inc.
  • 17.6. Apollo Endosurgery, Inc.
  • 17.7. Aspire Bariatrics, Inc.
  • 17.8. Bariatric Solutions GmbH
  • 17.9. Bariatric Solutions International
  • 17.10. BDB Limited
  • 17.11. Boston Scientific Corporation
  • 17.12. ConMed Corporation
  • 17.13. Cousin Biotech
  • 17.14. Districlass Medical
  • 17.15. Endalis
  • 17.16. Fractyl Health
  • 17.17. GI Dynamics, Inc.
  • 17.18. Helioscopie Medical Implants
  • 17.19. Intuitive Surgical
  • 17.20. Johnson & Johnson
  • 17.21. Lexel Medical
  • 17.22. MEDSIL
  • 17.23. Medtronic plc
  • 17.24. Obalon Therapeutics, Inc.
  • 17.25. Olympus Corporation
  • 17.26. ReShape Lifesciences, LLC
  • 17.27. Silimed
  • 17.28. Spatz FGIA
  • 17.29. Spatz Medical Ltd.
  • 17.30. USGI Medical, Inc.
  • 17.31. W. L. Gore & Associates

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ASPIRATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ASPIRATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ASPIRATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY STAPLING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY STAPLING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY STAPLING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY SUTURING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY SUTURING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY SUTURING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY LONG-TERM BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY LONG-TERM BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY LONG-TERM BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY SHORT-TERM BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY SHORT-TERM BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY SHORT-TERM BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY REUSABLE BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY REUSABLE BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY REUSABLE BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY SINGLE-USE BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY SINGLE-USE BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY SINGLE-USE BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY FREESTANDING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY FREESTANDING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY FREESTANDING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY BARIATRIC CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY BARIATRIC CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY BARIATRIC CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ACADEMIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ACADEMIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ACADEMIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY MULTIDISCIPLINARY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY MULTIDISCIPLINARY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY MULTIDISCIPLINARY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY SINGLE PRACTICE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY SINGLE PRACTICE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY SINGLE PRACTICE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 182. GCC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GCC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. GCC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 186. GCC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 188. GCC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. GCC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 190. GCC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 191. GCC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 192. GCC ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 215. G7 ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. G7 ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. G7 ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 218. G7 ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 219. G7 ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. G7 ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 221. G7 ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. G7 ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 223. G7 ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 224. G7 ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 225. G7 ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 226. NATO ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. NATO ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. NATO ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 229. NATO ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 230. NATO ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. NATO ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 232. NATO ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. NATO ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 234. NATO ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 235. NATO ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 236. NATO ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY PROCEDURE SETTING, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA ENDOSCOPIC WEIGHT LOSS THERAPY MARKET SIZE, BY WEIGHT LOSS CENTERS, 2018-2032 (USD MILLION)